Windlas Biotech Q2 FY27 Results: Standalone Net Profit ₹18.05 Crore on Total Income of ₹268 Crore
- Earnings
- Pharmaceuticals
Reviewed byRachit TripathiBlacklitt Research
Windlas Biotech (NSE: WINDLAS) reported total income of ₹267.77 crore and net profit of ₹18.05 crore for the quarter ended 30 Sep 2026, on a standalone basis, it said in a filing on 05 Nov 2026. The results were approved by the board on the same day and are unaudited.
Key highlights
Standalone
The company on its own, without its subsidiaries
- Total income: ₹267.77 crore, up 18.5% YoY and 5.7% QoQ
- Net profit and EPS: ₹18.05 crore, up 1.4% YoY; basic EPS ₹8.75, up 3.2% YoY
- Finance costs: ₹2.33 crore, up 129.7% YoY from ₹1.02 crore
- Buyback: 470,000 shares bought back for ₹47.00 crore in the six months
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 267.77 | 226.04 | +18.5% | 253.21 | +5.7% | |
| Revenue from operations | 263.91 | 222.40 | +18.7% | 248.10 | +6.4% |
| Other income | 3.86 | 3.65 | +5.9% | 5.11 | -24.5% |
| 18.05 | 17.80 | +1.4% | 17.65 | +2.3% | |
| Profit before tax | 23.30 | 23.59 | -1.2% | 22.94 | +1.6% |
| Finance costs | 2.33 | 1.02 | +129.7% | 1.65 | +41.5% |
| Depreciation | 7.59 | 7.60 | -0.1% | 7.21 | +5.4% |
| Tax expense | 5.25 | 5.79 | -9.3% | 5.28 | -0.7% |
| Net profit margin | 6.74% | 7.87% | -1.13 pp | 6.97% | -0.23 pp |
| EPS, basic (₹) | 8.75 | 8.48 | +3.2% | 8.46 | +3.4% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Income grew faster than profit this quarter. Total income rose 18.5% from the year-earlier quarter, while net profit rose 1.4% and profit before tax fell 1.2%. Revenue from operations, at ₹263.91 crore, carried most of the growth, and other income of ₹3.86 crore was 1.4% of total income.
Finance costs more than doubled, from ₹1.02 crore to ₹2.33 crore, a rise of 129.7%. Finance costs are 0.9% of total income, so the increase is small in absolute terms. The notes in the filing do not explain the change in finance costs.
Tax expense fell to ₹5.25 crore from ₹5.79 crore, which is 22.5% of profit before tax. The filing gives no reason for the lower tax charge against the year-earlier quarter.
Compared with the previous quarter, Q1 FY27, net profit rose 2.3% against a 5.7% rise in total income. Other income of ₹3.86 crore is 16.6% of profit before tax.
Windlas Biotech is a pharmaceutical company with one primarily reportable segment, pharmaceuticals, according to the notes. Its market value was ₹1,901 crore at the 05 Nov 2026 close of ₹921.25 a share. Its latest reported quarter, Q1 FY27, showed total income of ₹253.21 crore, up 17.6% YoY, and net profit of ₹17.65 crore, down 0.1% YoY.
The auditors draw attention to this matter, and their conclusion is not modified by it.
Inference
The filing records a buyback of 470,000 shares at ₹1,000 each, for ₹47.00 crore, completed through the tender offer route under a board resolution of 17 Apr 2026. After the buyback the company has 20,636,229 equity shares of face value ₹5. The filing also records a dividend of ₹6.30 per share, paid on 31 Jul 2026, aggregating ₹13.00 crore.
The filing states that Ashok Kumar Windlass resigned as Whole-time Director and Director from 5 Nov 2026, citing long-term succession planning, and was appointed Founder President from 6 Nov 2026, subject to shareholder approval, at remuneration of ₹1.56 crore a year. Who will succeed him as Whole-time Director is not stated, and neither is the date of the shareholder approval.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
